Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Xeris Biopharma Holdings Inc shares valued at $106,414 were sold by BORMANN-KENNEDY BARBARA-JEAN A on Dec 12 ’25. At $7.09 per share, BORMANN-KENNEDY BARBARA-JEAN A sold 15,000 shares. The insider’s holdings dropped to 142,500 shares worth approximately $1.0 million following the completion of this transaction.
Also, BARBARA-JEAN A BORMANN-KENNEDY purchased 15,000 shares, netting a total of over 105,150 in proceeds.
Before that, Hecht Beth had sold 16,667 shares from its account. In a trade valued at $116,781, the insider traded Xeris Biopharma Holdings Inc shares for $7.01 each. Upon closing the transaction, the insider’s holdings decreased to 16,667 shares, worth approximately $9.23 million.
As published in their initiating research note from Barclays on December 09, 2025, Xeris Biopharma Holdings Inc [XERS] has been an Overweight and the price target has been revised to $9. As of November 11, 2024, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for XERS. Earlier on March 28, 2024, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for XERS stock.
Analyzing XERS Stock Performance
On last trading session, Xeris Biopharma Holdings Inc [NASDAQ: XERS] plunged -1.55% to $6.99. The stock’s lowest price that day was $6.97, but it reached a high of $7.26 in the same session. During the last five days, there has been a surge of approximately 0.72%. Over the course of the year, Xeris Biopharma Holdings Inc shares have jumped approximately 113.11%. Shares of the company reached a 52-week high of $10.08 on 11/05/25 and a 52-week low of $3.14 on 01/13/25.
Support And Resistance Levels for Xeris Biopharma Holdings Inc (XERS)
According to the 24-hour chart, there is a support level at 6.89, which, if violated, would cause prices to drop to 6.78. In the upper region, resistance lies at 7.18. The next price resistance is at 7.36. RSI (Relative Strength Index) is 44.06 on the 14-day chart, showing neutral technical sentiment.
Is Xeris Biopharma Holdings Inc subject to short interest?
Stocks of Xeris Biopharma Holdings Inc saw a sharp steep in short interest on 2025-11-28 dropping by -1.65 million shares to 15.97 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 17.63 million shares. A decline of -10.35% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.72 of the overall float, the days-to-cover ratio (short ratio) decline to 5.72.
Which companies own the most shares of Xeris Biopharma Holdings Inc (XERS)?
In terms of Xeris Biopharma Holdings Inc share price expectations, FactSet research, analysts set an average price target of 13.5 in the next 12 months, up nearly 90.14% from the previous closing price of $7.1. Analysts anticipate Xeris Biopharma Holdings Inc stock to reach 18 by 2025, with the lowest price target being 9. In spite of this, 3 analysts ranked Xeris Biopharma Holdings Inc stock as Buy at the end of 2025. On August 28, 2023, Craig Hallum assigned a price target of “a Buy” to the stock and initiated coverage with a $4.50.
